Phase II Trial for Large ER-Negative Breast Cancers
NCT01869192
Completed
A primary objective of this study is to evaluate the in vivo response of tumor to chemotherapy through gene microarray analysis. Neoadjuvant treatment allows the unique opportunity to observe the in vivo effects of cytotoxic therapy on gene expression in tumor tissue. The investigators plan to evaluate several different questions by comparing gene profiles in different phases of treatment in this study. These are outlined below. Hypotheses 1. Chemotherapy enriches for tumor cell populations th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/11/2019
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Malignant Neoplasm of Female Breast
Register for Updates
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
NCT01581970
Completed
This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line chemotherapy other than a cetuximab containing regimen will be treated with standard of care weekly cetuximab and twice daily low dose oral cyclophosphamide for 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2019
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Hematopoietic Stem Cell Transplant for Fanconi Anemia
NCT01071239
Completed
The trial proposed is a single arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and anti-thymocyte globulin (ATG- a non-chemotherapy drug whose role is to kill your immune system) for the treatment of patients with Fanconi anemia who have severe aplastic anemia (SAA), or myelodysplastic syndrome (MDS) or acute myeloge... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/03/2019
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Fanconi Anemia
Register for Updates
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01955434
Completed
This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 alone or with cyclophosphamide works in treating patients with multiple myeloma that has returned or does not respond to treatment. Biological therapies, such as SMAC mimetic LCL161, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2019
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
NCT03575234
Withdrawn
This phase I trial studies the side effects of nivolumab and IRX-2 and how well they work in treating participants with stage III-IVA oral cavity cancer or human papillomavirus (HPV)-positive oropharyngeal cancer that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. IRX-2 may "turn on" the immune system and stimulate an immune response against tumor cells. Giving nivolumab and IRX-2 followed by surgery may work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2019
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Register for Updates
SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
NCT02013375
Terminated
Related donor stem cell transplantation using the alemtuzumab/ TBI platform has been shown to be a safe strategy to cure severe sickle cell disease. However, due to a lack of suitable donors, many patients cannot benefit from this strategy. Alternative donor sources are desperately needed to fill this gap. Nearly all patients will have a haploidentical family member who would be able to donate. The use of post transplantation cyclophosphamide has greatly improved the outcome of haploidentical st... Read More
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
08/22/2019
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Sickle Cell Disease
Register for Updates
Stem Cell Transplantation for Fanconi Anemia
NCT00167206
Terminated
The purpose of this study is to determine whether thymic shielding during total body irradiation can be given and whether it will reduce the risk of infections in Fanconi Anemia patients undergoing alternate donor (not a matched sibling) stem cell transplants.
Gender:
ALL
Ages:
Between 1 day and 18 years
Trial Updated:
08/21/2019
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Fanconi Anemia
Register for Updates
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
NCT00866749
Completed
Objectives: A. Primary objective: 1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM) in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). B. Secondary objective: 1. To evaluate the prognostic significance of minimal residual disease in bone marrow samples at the end of induction and at the end of consolidation in this group of patients. 2. To prospectively evaluate gene hyperm... Read More
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
08/21/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Register for Updates
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
NCT01454596
Completed
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with gliomas that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patient's white... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/16/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
Register for Updates
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT00770224
Completed
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2019
Locations: Providence Cancer Center at Providence Hospital, Mobile, Alabama +113 locations
Conditions: Lymphoma
Register for Updates
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
NCT01253460
Terminated
The goal of this clinical research study is to learn if sapacitabine given in combination with 2 standard drugs (cyclophosphamide and rituximab) can help to control CLL and SLL. The safety of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
NCT00656123
Completed
The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an immunomodulatory dose of Cyclophosphamide
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/12/2019
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Colorectal Cancer, Metastatic Cancer
Register for Updates